Cupid Ltd., a prominent manufacturer and supplier of male and female condoms, lubricant jelly, and IVD Kits, has announced a substantial upward revision of its financial guidance for the fiscal year 2027. The company now anticipates FY27 sales to reach Rs 800 crore, with net profit projected at Rs 250 crore.
The positive outlook follows an expected strong performance in the September quarter of FY27, where revenue is forecast to exceed Rs 200 crore. This momentum is expected to continue through the third and fourth quarters of the fiscal year.
Key Drivers for Upward Revision
Several strategic factors are contributing to Cupid's enhanced projections:
- Domestic FMCG Expansion: Continued growth and expansion in the domestic Fast-Moving Consumer Goods (FMCG) segment.
- Palava Facility: Progress towards the imminent operationalization of the Palava manufacturing facility.
- Healthcare Portfolio: Sustained growth across the company’s healthcare and personal care product lines.
- Market Visibility: Improved visibility and performance across both domestic and international markets.
Strategic Developments and Investments
In addition to its operational strengths, Cupid Ltd. has undertaken several strategic initiatives:
- Warrant Conversion: The company approved the conversion of up to 30 lakh warrants of Baazar Style Retail Limited into an equivalent number of equity shares at Rs 328.25 per share.
- South African Venture: Cupid received in-principle approval for a new manufacturing venture in South Africa. This facility aims to support local manufacturing and serve as a platform for expansion across Africa and other international markets, adopting an asset-light model.
- GII Healthcare Partnership: The strategic healthcare partnership with GII Healthcare Investment Limited has been strengthened through an additional $5 million follow-on investment.
These initiatives underscore Cupid’s commitment to reinforcing its healthcare and personal care platform, expanding its FMCG portfolio, and enhancing manufacturing capabilities for both international B2B healthcare and domestic consumer businesses.
Market Performance and Index Inclusions
Shares of Cupid have demonstrated robust performance, surging by 258.94 percent over the past six months. During the September quarter, the company's shares were included in significant market indices, including the BSE Group ‘A’, NIFTY Small Cap 250, and the FTSE Emerging Markets All Cap Index, reflecting its growing market presence and investor confidence.